Result of WRAP Retail Offer and TVR

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the "Fundraising RNS") and the WRAP Retail Offer announcement published on 17 March 2026 at 7:01 a.m. (the "WRAP RNS"), announces the result of the WRAP Retail Offer and provide an update on the Fundraising.

The Company has raised gross proceeds of £468,746.82 from the WRAP Retail Offer at the Issue Price and will, accordingly, issue 7,812,447 WRAP Retail Offer Shares pursuant to the WRAP Retail Offer.

Accordingly, in total, the Subscription and the WRAP Retail Offer have raised gross proceeds of approximately £6.468m for the Company, via the issue of the 100,000,000 Subscription Shares and the 7,812,447 WRAP Retail Offer Shares all at the Issue Price.

Additionally, as detailed in the Fundraising RNS, the Company is also issuing 12,000,000 Value Payment Shares and 1,375,000 Fee Shares at the Issue Price.

The allotment of the Subscription Shares, WRAP Retail Offer Shares, Value Payment Shares and Fee Shares requires prior approval by the Company's Shareholders at the General Meeting which is scheduled for 11.00 a.m. on 7 April 2026. Contingent on approval of the Resolutions at the General Meeting Admission is expected to take place at 8.00 a.m. on 8 April 2026.

Admission and Total Voting Rights

Application will be made for a total of 121,187,447 new Ordinary Shares to be admitted to trading on AIM. It is expected that, contingent on approval of the Resolutions at the General Meeting, Admission of the 100,000,000 Subscription Shares, 12,000,000 Value Payment Shares, 7,812,447 WRAP Retail Offer Shares and 1,375,000 Fee Shares will become effective and dealings in those shares will commence at 8:00 a.m. on 8 April 2026.

Upon admission of the Subscription Shares, the Value Payment Shares, the WRAP Retail Offer Shares and the Fee Shares, the Company's issued ordinary share capital will comprise 623,911,379 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. This figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

All new Ordinary Shares, including the Subscription Shares, the Value Payment Shares, the WRAP Retail Offer Shares and the Fee Shares, will be issued free of all liens, charges and encumbrances and will, from respective admissions, rank pari passu in all respects with the Company's existing Ordinary Shares.

Terms used but not defined in this announcement have the same meaning as set out in the Fundraising RNS and / or WRAP RNS.

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.